ViCapsys Life Sciences Appoints Federico Pier as Permanent Chief Executive Officer

Rhea-AI Summary

ViCapsys Life Sciences has appointed Federico Pier as the permanent CEO, effective February 15, 2022. Pier, who has been the interim CEO since August 2020, is credited with establishing a solid foundation for the company’s mission in developing therapeutic solutions, particularly in the field of diabetes. With over 25 years of experience in finance and life sciences, his leadership is expected to guide the company through its expansion into additional therapeutics. ViCapsys focuses on proprietary products for transplantation therapies and post-surgical needs.

Positive

• Federico Pier has extensive experience in life sciences and structured finance, enhancing leadership.
• His appointment is expected to strengthen ViCapsys' strategic direction and expansion efforts.

Negative

• None.

Brings significant financial and managerial experience to guide next phase of development

SUWANEE, GA / ACCESSWIRE / April 12, 2022 / ViCapsys Life Sciences, Inc., (OTC:VICP) ("ViCapsys" or the "Company") announced the appointment of Federico Pier as Chief Executive Officer of ViCapsys, effective February 15, 2022. Mr. Pier had been serving as interim President & CEO since August 2020.

"Over the last two years as our interim CEO, Federico has done an exceptional job of laying the necessary foundation for ViCapsys to further its mission of achieving positive therapeutic outcomes for various indications with our proprietary technology," stated Michael Yurkowsky, Director of ViCapsys. "Federico's business acumen, combined with his significant experience in working with life sciences companies, makes him the ideal candidate for the permanent position."

"This is a pivotal time for ViCapsys, and I am honored to lead the Company through our continued expansion into additional therapeutics beyond Type 1 diabetes," stated Mr. Pier. "I look forward to sharing the next phase of our corporate development, as well as advancements for these critical indications."

Mr. Pier has more than 25 years of experience in reverse mergers, structured finance, convertible debt, and equity. This includes his current role as the Managing Director of YPH, LLC, a multifamily office investing in life sciences, energy, and technology. It also includes prior roles as Senior Director at Oppenheimer & Co. and as Managing Director at Bear Stearns. He holds a Bachelors' degree from the University of North Texas and an MBA from the Graduate School of Management at the University of Dallas.

About ViCapsys Life Sciences

ViCapsys Life Sciences, Inc. focuses on the development and commercialization of VICAPSYN, a proprietary product. The company's product is applied to transplantation therapies and related stem-cell applications in the transplantation field. It also develops VYBRIN, a product based on CXCL12 for prevention of post-surgical adhesions in abdominal surgery, coating of implantable medical devices and other implants to eliminate fibrosis, and wound healing with a focus on diabetic ulcers. For more information, please visit https://vicapsys.com/.

Investor Contact

Alpha IR Group
Jackie Marcus or Chris Hodges
VICP@alpha-ir.com

SOURCE: ViCapsys Life Sciences

View source version on accesswire.com:
https://www.accesswire.com/697147/ViCapsys-Life-Sciences-Appoints-Federico-Pier-as-Permanent-Chief-Executive-Officer

FAQ

What is the significance of Federico Pier's appointment as CEO of ViCapsys?

Federico Pier's appointment as CEO is significant as he has served as interim CEO since 2020, providing continuity and leadership with a strong background in life sciences and finance.

When did Federico Pier officially become CEO of ViCapsys?

Federico Pier officially became the CEO of ViCapsys on February 15, 2022.

What are the key qualifications of Federico Pier?

Federico Pier has over 25 years of experience in reverse mergers, structured finance, and life sciences, previously holding senior positions at Oppenheimer & Co. and Bear Stearns.

What is ViCapsys Life Sciences focused on?

ViCapsys Life Sciences focuses on developing and commercializing proprietary products for transplantation therapies and preventing post-surgical adhesions.